Bioelectronics Corp (BIEL)

[DewmBoom]

$BIEL: Marketing Expansion/FDA Clearance

If you read the last couple of sentences in the CEO quote below, you will know that all we are waiting for is for the FDA to accept the back pain clinical trial that was reviewed by them during the May 9 meeting and clear the Actipatch for full body. That is all. The reason for this is because the exact knee Actpatch which is already approved will be sitting in different boxes for different applications, with the KT.

We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line.

Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:

Prescription coverage for the majority of the 56 million populations of England and Wales.

A drug tariff listing for reimbursement is expected to accelerate reimbursement clearance request in other nations.

Has the potential to open the US market to the 90 million people with prescription payment coverage in Health Maintenance Organizations (HMO’s), Accountable Care Organization, and other third party payers to provide and pay the cost of ActiPatch therapy.

The ActiPatch registry studies report that people buy the device because it is effective, drug-free, has no harmful side effects and overall improves quality of life. We are continually working to solve existing minor issues with the use of ActiPatch. To improve the product, we are introducing custom-design kinesiology tape strips to attach the device to the body. Aside from improving user comfort, this allows us to promote a single multi-purpose box with the added benefit of reducing retail shelf space. We believe this will then allow us to sell the 7-day trial devices from pharmacy shelves.

http://www.bielcorp.com/investors/letter-from-the-president/